What BioGenes Technologies does

BioGenes Technologies is a Malaysian biotech company that designs, develops, and commercializes animal-free aptamer-based diagnostics and biosensors. Its core technology is synthetic nucleic-acid aptamers that bind to specific molecular targets, positioned as an ethical and supply-chain-stable alternative to traditional animal-derived antibodies. The product architecture spans three integrated platforms: APTCAD (cloud-based biocomputational software for in-silico aptamer design and molecular docking), APTFAB (on-demand aptamer and oligonucleotide synthesis using Kilobaser tabletop machines, offered as a service or via equipment leasing), and APTSENS (an electrochemical biosensor platform adaptable to healthcare, food production, and environmental monitoring). Through its wholly-owned subsidiary Allen Healthcare Products (AHP), the company also manufactures medical-grade diagnostic test kits for infectious diseases, women's health, and drug abuse screening, with annual capacity of 10 million kits at a Penang facility acquired in 2023.

The business operates a B2B go-to-market selling into healthcare providers, research institutions, and industrial clients across at least five verticals — clinical diagnostics, food production, environmental monitoring, veterinary and agriculture, and academia. Revenue is generated across multiple streams: one-time product sales of aptamer sequences, oligos, biosensors, and screen-printed electrodes; subscription-based access to the APTCAD software; professional services including training and consulting; equipment leasing for APTFAB machines; and hardware/manufacturing revenue through AHP. Pricing is uniformly quote-based with no public rate cards, and sales are driven by direct email inquiry and LinkedIn engagement rather than channel partners. The company is venture-backed (US$5.7M Series A led by Pembangunan Ekuiti in January 2023, prior seed from ANTLER, and government grants from MTDC and CRADLE) and is planning geographic expansion into Indonesia and the Philippines.

Name

BioGenes Technologies

Legal name

Biogenes Technologies Sdn. Bhd.

Website

https://biogenestech.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

BioGenes Technologies is a Malaysian biotech that designs and commercializes animal-free aptamer-based diagnostics and electrochemical biosensors, serving clinical, food, environmental, veterinary, and academic customers with three integrated platforms (APTCAD, APTFAB, APTSENS) and medical-grade manufacturing via subsidiary Allen Healthcare Products.

Ownership category

akta.pro rank

Product category

Aptamer-based Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Aptamer diagnostics
• Molecular biosensors
• Synthetic antibodies
• Diagnostic test kits
• Biotech manufacturing

Headquarters

HQ city

Kajang

HQ country

Malaysia

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Aptamer Products & Synthesis: Custom aptamer sequences, oligonucleotides, and primers synthesized on-demand. Revenue from direct product sales and Kilobaser machine leasing/purchasing arrangements.
2. Biosensor Products & Services: APTSENS electrochemical biosensor platform products, SPE fabrication, biosensor optimization services, and training. Manufacturing handled by subsidiary Allen Healthcare Products (AHP).
3. Software Services (APTCAD): Cloud-based aptamer design software offered as a service for in-silico testing before laboratory work.
4. Training & Consulting Services: Aptamer training, biosensor training, specialized training programs, and biocomputation simulation services offered to academic and commercial clients.
5. Manufacturing (via AHP Subsidiary): Medical-grade manufacturing of diagnostic test kits including infectious disease tests, women's health tests, and drug abuse screening kits, produced at the Penang facility.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

BioGenes Technologies develops and commercializes aptamer-based synthetic antibody diagnostics through three integrated platforms: APTCAD (computational aptamer design software), APTFAB (on-demand aptamer synthesis), and APTSENS (electrochemical biosensor platform). The company manufactures diagnostic test kits and biosensor devices at scale through its subsidiary Allen Healthcare Products (AHP) in Penang, Malaysia, serving healthcare, agricultural, aquaculture, and industrial clients.

Product overview

BioGenes Technologies operates a multi-platform product portfolio centered on animal-free aptamer technology for diagnostics and life science applications. The core offerings include three integrated platforms: APTCAD (cloud-based biocomputational software for aptamer design and in-silico testing), APTFAB (on-demand aptamer synthesis service using Kilobaser equipment), and APTSENS (electrochemical biosensor diagnostic platform). Additional services span aptamer design, biocomputation simulation, biosensor products, SPE fabrication, and full-scale manufacturing (via subsidiary AHP). The company also offers acquired products including Allen Healthcare Products (specializing in infectious disease, women's health, and drug abuse test kits), Arowana fish gender testing kits (licensed from UKM), and launched two new diagnostic products in 2024: a paddy disease field test kit and an aptamer-based HPV staining kit.

Differentiator

Problem solved

Functional benefit

Products and services

• APTCAD

Quantifiable outcome

• Reduced laboratory development time through APTCAD in-silico testing before wet lab work
• +2 more outcomes

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core and major.

• Allen Healthcare Products (AHP)coreOEM/ Whitelabel/ Licensing Partner · 22 December 2023Acquired as subsidiary in late 2023 to expand production capacity for diagnostic test kits. AHP is a medical-grade manufacturer specializing in test kits for infectious diseases, women's health, and drug abuse. The acquisition increased annual kit production capacity to 10 million units and enabled entry into Southeast Asian market.
• Various Malaysian UniversitiesmajorStrategic or Co-development Partner · 1 January 2021Initiated collaboration with multiple Malaysian universities in 2021 to accelerate development of diagnostic products in healthcare. Company engages in academic and commercial collaborations.
• Universiti Kebangsaan Malaysia (UKM)coreTechnology or Integration · 1 January 2016Licensed Arowana fish gender testing technology using DNA-based biosensor from Malaysian university UKM in 2016. This was the company's first licensed technology.
• KilobasermajorTechnology or IntegrationPartnership for APTFAB tabletop aptamer/nucleotide synthesis machines. Biogenes offers leasing and purchasing arrangements for Kilobaser machines to place APTFAB units on customer premises for on-demand aptamer synthesis.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AM Biotech: Aptamer and molecular services company providing custom aptamer and oligonucleotide synthesis, comparable to BioGenes' APTFAB service line.
• Aptamer Group: UK-based custom aptamer selection and development services with Optimer binders for diagnostics and therapeutics. Most direct comparable on the aptamer services side, competing for academic and commercial customers needing custom aptamer sequences.
• NeoVentures Biotechnology: Canadian aptamer technology company offering custom aptamer selection, aptamer-based diagnostics, and biosensor development. Closely comparable on aptamer discovery-to-diagnostic workflow and target customer base.
• BasePair Biotechnologies: US-based aptamer discovery and development services company offering custom aptamer selection and bioinformatics tools. Comparable in offering computational/in-silico aptamer design and custom synthesis services to researchers.

Emerging players

• Adagene: Clinical-stage biotech using computational/AI-powered platforms to engineer antibody-based therapeutics. Comparable AI/ML-enabled biologic design approach but focused on therapeutic antibodies rather than diagnostics.

Broad incumbents

• SomaLogic: Large-scale aptamer-based proteomics platform (SomaScan) serving pharma, clinical research, and academic customers. Significantly larger and better-capitalised, but operates in the same aptamer-based biomarker/diagnostic space.
• Bio-Rad Laboratories: Global life science and clinical diagnostics manufacturer with a broad portfolio of immunoassay kits, biosensors, and laboratory instruments. Comparable on biosensor/diagnostic kit manufacturing and clinical customer base, though much larger and not aptamer-focused.
• AbCellera Biologics: Public antibody discovery platform using AI/ML and high-throughput screening. Adjacent technology category to BioGenes' synthetic antibody alternative (aptamer) approach, targeting similar pharma/biotech customers.

Regional players

• INEX Innovate: Singapore-based molecular diagnostics company developing prenatal and oncology tests for Southeast Asian markets. Comparable as a SEA-based diagnostics developer, though focused on nucleic-acid-based MDx rather than aptamer biosensors.
• Malaysian Genomics Resource Centre: Malaysian molecular diagnostics and genomics services company offering genetic screening and testing. Local Malaysian peer with overlapping clinical diagnostics customer base and SEA regional ambitions.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/biogenestech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioGenes Technologies